CLN2 Disease
Also known as: Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) / Neuronal ceroid lipofuscinosis type 2 / Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) / CLN2 Disorder / Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Drug | Drug Name | Drug Description |
---|---|---|
DB13173 | Cerliponase alfa | An enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB13173 | Cerliponase alfa | Cation-independent mannose-6-phosphate receptor | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB13173 | Cerliponase alfa | 1 / 2 | Active Not Recruiting | 1 |
DB13173 | Cerliponase alfa | 1 / 2 | Completed | 2 |
DB13173 | Cerliponase alfa | 2 | Completed | 1 |
DB13173 | Cerliponase alfa | Not Available | Active Not Recruiting | 1 |
DB13173 | Cerliponase alfa | Not Available | Approved for Marketing | 1 |